Journal Article

Ninety-Six—Week Efficacy of Combination Therapy with Lamivudine and Tenofovir in Patients Coinfected with HIV-1 and Wild-Type Hepatitis B Virus

F. Bani-Sadr, P. Palmer, C. Scieux and J. M. Molina

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 39, issue 7, pages 1062-1064
Published in print October 2004 | ISSN: 1058-4838
Published online October 2004 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/424012
Ninety-Six—Week Efficacy of Combination Therapy with Lamivudine and Tenofovir in Patients Coinfected with HIV-1 and Wild-Type Hepatitis B Virus

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus (HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination therapy with lamivudine and tenofovir. The use of combination therapy with lamivudine and tenofovir for the treatment of HBV infection is very promising in the treatment of HIV/HBV coinfection.

Journal Article.  856 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.